Lingbo Biotechnology (Hangzhou)
Biologic artificial blood vessels for tissue engineering
About Lingbo Biotechnology (Hangzhou)
Lingbo Biotechnology (Hangzhou) Co., Ltd. is a biotechnology firm established in 2019, specializing in the field of tissue-engineered medical devices. The company is focused on the research and development of biologic artificial blood vessels. Its main product under development is the "Skeletal Acellular Vessels" (SAV), a biological artificial blood vessel that is positioned to be a pioneering product of its kind in the Chinese market.
The company was founded by Kong Deling, a professor and doctoral supervisor at the College of Life Sciences at Nankai University. Kong is a recipient of the National Science Fund for Distinguished Young Scholars and leads an innovation team recognized by the Ministry of Education.
Lingbo Biotechnology operates in the medical device sector, specifically targeting the market for artificial organs and organ protection products. The company's business model revolves around the research, development, clinical trials, and eventual production and commercialization of its proprietary medical devices. Since its inception, the company has successfully completed several funding rounds, including a Series A+ round in June 2024 led by Tasly Holding Group, a Series A round in November 2023, a Pre-A round in April 2021, and an angel round in August 2020. These funds are allocated to advance clinical trials for existing products and to support the research and development of new applications, such as artificial blood vessels for cardiac bypass surgery.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 13.3/100
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2024 | — | — | Tasly Capital | ↗ |
| SERIES A✓Equity / VC | Nov 2023 | $14M | $55M | BGI Co-Win · Tigeryeah Capital · Tailong Investment · Insight Capital | ↗ |
Growth signals
Latest recorded traffic for Lingbo Biotechnology (Hangzhou) is 160 monthly website visits, down 67.3% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Lingbo Biotechnology (Hangzhou) in the Hangzhou ecosystem
The Lingbo Biotechnology (Hangzhou) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- ICInsight Capital
Series A5 investors entered at this stage
Pan-Lin Asset Management
BGI Co-Win- TCTigeryeah Capital
- TITailong Investment
Tasly Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lingbo Biotechnology (Hangzhou) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lingbo Biotechnology (Hangzhou)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.